Oral Care of Patients Treated With Anti-RANK-ligand Antibodies for a Giant Cell Tumour

Oral Care of Patients Treated With Anti-RANK-ligand Antibodies for a Giant Cell Tumour: Retrospective Study at the University Hospitals of Strasbourg

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05542524

Acronym

DENO

Enrollment

Registered

2022-09-15

Start date

2022-09-01

Completion date

2023-08-31

Last updated

2023-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Giant Cell Tumors

Keywords

Giant Cell Tumors, Anti-RANK-ligand antibodies

Brief summary

Giant cell tumors are mostly benign tomoral processes, most often responsible for areas of osteolysis in the metaphysoepiphyseal area of long bones, representing 5-6% of primary bone tumors. The bone weakening induced by these beaches leads to pain and risk of fracture, and this is what leads the patient to consult. These tumors are found particularly in the young adult population between 20 and 40 years old, are locally aggressive, but malignant transformations and metastases (pulmonary) are quite rare. In this study, the investigators wish to retrospectively study the oral care of patients who presented with a giant cell tumor and were treated with Denosumab at the University Hospital of Strasbourg and their associated oral follow-up

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult subject, having presented a giant cell tumor treated with adjuvant or neoadjuvant denosumab at the HUS from 01/01/2014 to 08/31/2022. * Subjects who have not expressed their opposition to the reuse of their data for scientific research purposes.

Exclusion criteria

* Subject having expressed their opposition to the retrospective reuse of their data for scientific research purposes * Pathology finally labeled other than giant cell tumour. * Treatment with denosumab was not initiated because of death, change in treatment protocol, etc. * Absence of oral follow-up element.

Design outcomes

Primary

Measure	Time frame
Number of Decayed, Missing, and Filled Permanent Teeth (DMFT)	Files analysed retrospectively from from January 01, 2014 to August 31, 2022 will be examined

Countries

France

Outcome results